Knopp Neurosciences Forms New Parent Company to Expand Operations and Mission
Knopp Neurosciences Inc. announced that it has formed a new parent entity called Knopp Biosciences LLC to expand operations with the goal of becoming a more broadly integrated biopharmaceutical company.
The corporate restructuring follows an August 2010 agreement under which Biogen Idec secured exclusive global rights to develop and commercialize KNS-760704 (dexpramipexole) from Knopp Neurosciences (“KNS”). KNS remains the licensor of assets associated with KNS-760704 but has distributed its other assets and operations to Knopp Biosciences, with a corresponding shareholder recapitalization. The transferred assets and operations include the discovery research activities of KNS, which are directed to pharmacological mediation of mitochondrial disease mechanisms.
“Knopp Biosciences establishes a platform for corporate growth while signaling the potential to apply our discovery research in therapeutic areas beyond neuroscience,” said Michael Bozik, M.D., President and CEO. “While expanding our discovery research capabilities, Knopp Biosciences will take steps toward becoming a more integrated company with both development and commercialization activities.” He also noted that Knopp Biosciences will support the role of KNS in the licensing arrangement with Biogen Idec, which, as previously reported, expects to initiate Phase 3 development of KNS-760704 in amyotrophic lateral sclerosis (ALS) in the first half of 2011.
Knopp Biosciences remains on Pittsburgh’s South Side at the street address of KNS.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
